A practical reference on REV-ERB agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-30. Anything still debated is marked as such rather than presented as settled.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
In 1896, the engineer Wolfram Fuchs, based on his experience with numerous X-ray examinations, recommended keeping the exposure time as short as possible, staying away from the tube, and covering the skin with Vaseline. In 1897, Chicago doctors William Fuchs and Otto Schmidt became the first users to have to pay compensation to a patient for radiation damage. In 1901, dentist William Herbert Rollins (1852-1929) called for using lead-glass goggles when working with X-rays, for the X-ray tube to be encased in lead, and for all areas of the body to be covered with lead aprons. He published over 200 articles on the potential dangers of X-rays, but his suggestions were long ignored. A year later, Rollins wrote in despair that his warnings about the dangers of X-rays were not being heeded by either the industry or his colleagues. By this time, Rollins had demonstrated that X-rays could kill laboratory animals and induce miscarriages in guinea pigs. Rollins' achievements were not recognized until later. Since then, he has gone down in the history of radiology as the "father of radiation protection". He became a member of the Radiological Society of North America and its first treasurer.
=== One-Pot Synthesis === One-pot reactions involve combining all reactants simultaneously under appropriate conditions. This straightforward approach has proven successful for many simpler cage structures, particularly those formed through imine condensation. The success of one-pot synthesis often depends on the reversible nature of bond formation, allowing the system to self-correct and converge on the thermodynamically favored product. The reaction conditions, such as temperature, solvent choice, and concentration, play crucial roles in determining the outcome. For example, in imine cage synthesis, polar aprotic solvents like dichloromethane or chloroform are often preferred as they facilitate imine formation while allowing the removal of water byproduct. Additionally, techniques such as slow addition of components or temperature control can be employed to enhance selectivity towards the desired cage product.
i.e., independently from the initial size of the susceptible population the disease can never cause a proper epidemic outbreak. As a consequence, it is clear that both the basic reproduction number and the initial susceptibility are extremely important.
"Sympathetic skin response versus maximum motor and sensory conduction velocity to detect subclinical neuropathy in non-insulin-dependent diabetics". Acta Neurologica Belgica. 91 (4): 213–22. PMID 1746243. Hilz, Max J.; Stemper, Brigitte; Axelrod, Felicia B. (1 May 1999). "Sympathetic skin response differentiates hereditary sensory autonomic neuropathies III and IV". Neurology. 52 (8): 1652–1657. doi:10.1212/wnl.52.8.1652. PMID 10331694. S2CID 24227146. Tsementzis, S A; Hitchcock, E R (1 April 1985). "The spoon test: a simple bedside test for assessing sudomotor autonomic failure". Journal of Neurology, Neurosurgery & Psychiatry. 48 (4): 378–380. doi:10.1136/jnnp.48.4.378. PMC 1028306. PMID 3998743. Khurana, Ramesh K.; Russell, Colin (April 2017). "The spoon test: a valid and reliable bedside test to assess sudomotor function". Clinical Autonomic Research. 27 (2): 91–95. doi:10.1007/s10286-017-0401-2. PMID 28188384. S2CID 8755293.
=== United States === Pizza Hut's first television commercial was produced in 1965 by Bob Walterscheidt for the Harry Crow agency in Wichita, and was entitled "Putt-Putt to the Pizza Hut". The ad looks just like an old movie and is set in fast motion. It features a man in a business suit and tie, played by Ron Williams, who was then a production manager for Wichita's ABC affiliate KAKE-TV, as he orders take-out, leaves his house, and gets into his 1965 Mustang JR to drive to Pizza Hut, where he is chased by a variety of townspeople, portrayed by neighborhood kids, Walterscheidt and his daughter, and various employees for Harry Crow and KAKE-TV. He goes inside Pizza Hut to pick up his pizza and drives home. People eat all the pizza before the man who ordered it can get any, which makes the man very upset, so he calls Pizza Hut again. The ad first aired on November 19, 1966, during halftime of the Notre Dame vs. Michigan State "Game of the Century", and dramatically increased sales for the franchise. "Putt-Putt to the Pizza Hut" ran on TV for eight years and was nominated for a Clio Award. Until early 2007, Pizza Hut's main advertising slogan was "Gather 'round the good stuff". From 2008 to 2009, the advertising slogan was "Now You're Eating!" From 2009 to 2012, the advertising slogan was "Your Favorites. Your Pizza Hut" From 2012 to 2016, the advertising slogan was "Make it great", a variation of the 1987–1995 slogan "Makin' it great!". From 1995 to 1999, the slogan was "You'll love the stuff we're made of". The advertising slogan is currently "No one outpizzas the hut".
Sources: en.wikipedia.org
=== Antigen recognition === Garcia's earliest research as a graduate student at Johns Hopkins University focused on understanding how anti-idiotyopic antibodies recognize peptide antigens. As a postdoctoral scholar at The Scripps Research Institute, Garcia conducted a groundbreaking study that revealed how T cells of the immune system survey peptides presented by major histocompatibility complex proteins (MHC), thus allowing them to distinguish between "self" and "non-self". Garcia's research led to the first visualization of a T cell receptor (TCR) bound to a peptide-MHC (pMHC) complex and was published in the journal Science in 1996. Garcia's 1996 article on the TCR-MHC interaction has had broad impact in the fields of immunology and immunotherapy. At Stanford University, the Garcia Laboratory reported the structure of the pre-B cell receptor (pre-BCR) in 2007, which revealed how pre-BCRs oligomerize to signal in the absence of antigen. Garcia's group has also authored several additional landmark articles exploring various aspects of TCR-pMHC interactions, including the first structure of a γδ TCR-pMHC complex, the molecular basis for dual recognition of "self" and "foreign" MHCs by TCRs, insights into the germline basis of TCR/MHC interactions, the extent of cross-reactivity in the TCR repertoire, and elucidation of the structural trigger for TCR signaling. In Garcia's most recent work, his lab developed a peptide-MHC library technology that has enabled the discovery of antigens for orphan T cell receptors, such as those resident in tumors.
== Reactions == Nitrile groups in organic compounds can undergo a variety of reactions depending on the reactants or conditions. A nitrile group can be hydrolyzed, reduced, or ejected from a molecule as a cyanide ion.
=== Lotion === Lotions are similar to solution but are thicker and tend to be more emollient in nature than the solution. They are usually oil mixed with water, and more often than not have less alcohol than solution. Lotions can be drying if they contain a high amount of alcohol.
=== Foundation Phase === The Foundation Phase lasts 18 months and includes coursework in basic, clinical, and social sciences. It features nine medical science courses, each lasting four to six weeks, as well as two 18-month courses focusing on basic clinical skills (such as history-taking, physical examination, and professionalism) and the social and health systems, covering topics like social and cultural factors affecting health, ethics, and policy. The Foundation Phase is primarily completed in academic settings, including lectures, laboratories, seminars, and small-group sessions, but also incorporates several weeks of clinical experience.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.